Trials / Completed
CompletedNCT02275910
Phase 1 Study of E7090 in Subjects With Solid Tumor
A Phase 1 Study of E7090 in Subjects With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7090 |
Timeline
- Start date
- 2014-10-28
- Primary completion
- 2021-09-03
- Completion
- 2021-09-03
- First posted
- 2014-10-27
- Last updated
- 2025-12-16
- Results posted
- 2025-12-16
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02275910. Inclusion in this directory is not an endorsement.